612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II

Lack of efficacy of levocarnitine for the treatment of pegylated asparaginase-related hepatotoxicity during induction or salvage chemotherapy in adults with acute lymphoblastic leukemia

Clinical and molecular characteristics of Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia with central nervous system relapse versus systemic relapse

Metabolic and genetic determinants of severe asparaginase toxicities in adolescent and young adult acute lymphoblastic leukemia

Long term follow up for newly diagnosed BCR ABL1 negative B cell acute lymphoblastic leukemia from China 10 year outcome of RJ ALL 2014 protocol

Severe toxicities in survivors of pediatric and adolescent acute lymphoblastic lymphoma A population based study in Ontario Canada

Mixed phenotype acute leukemia Clinical characteristics and real world outcomes

Prognosis in adults with ph positive B ALL in first complete remission without minimal residual disease after blinatumomab consolidation is influenced by minimal residual disease =10 4 pre blinatumomab

MRD guided outcome analysis of ponatinib plus hyper CVAD versus historical imatinib in ph positive ALL Impact of early response and dose adjusted ponatinib

Safety and efficacy of carniospinal irradiation CSI before CAR T cell therapy in patients with acute lymphoblastic leukemia ALL with central nervous system CNS disease A potential role for CSI beyond cell killing and into immune priming

Prevalence of TPMT and NUDT15 diplotypes in Mexican children with B cell acute lymphoblastic leukemia

Cell cycle related genetic variants are frequently acquired at relapse of acute lymphoblastic leukemia and predict worse post relapse prognosis

Osteonecrosis risk in adult ALL Insights from real world clinical laboratory data in eighty seven patients treated with peg asparaginase

Disease status at initiation of blinatumomab and depth of response after cycle 1 are associated with survival in Philadelphia chromosome positive B cell acute lymphoblastic leukemia patients treated with blinatumomab and tyrosine kinase inhibitors

Prospective analysis and clinical implications of therapy related clonal hematopoiesis in adolescent and young adult survivors of acute lymphoblastic leukemia

Unwelcome guests Risk factors for multidrug resistant bacterial infections in adults with acute lymphoblastic leukemia

Serum neurofilament light chain NfL as a biomarker for chemotherapy induced peripheral neuropathy CIPN in pediatric acute lymphoblastic leukemia ALL